title: Protective Effect of a Synbiotic against Multidrug-Resistant Acinetobacter baumannii in a Murine Infection Model.
abstract: This study investigated the ability of the probiotic Bifidobacterium breve strain Yakult (BbY) to protect against infection, as well as the potentiation of BbY activity by the synbiotic combination of BbY and prebiotic galactooligosaccharides (GOS). The study employed a mouse model of lethal intestinal multidrug-resistant Acinetobacter baumannii (MDRAb) infection. The endogenous intestinal microbiota was disrupted by the administration of multiple antibiotics, causing the loss of endogenous Bifidobacterium Oral infection of these mice with MDRAb resulted in marked growth of this organism. Additional treatment of the infected mice with a sublethal dose of 5-fluorouracil (5-FU) induced systemic invasion by MDRAb and subsequent animal death. The continuous oral administration of BbY increased the survival rate and inhibited the intestinal growth and invasion by MDRAb in the infection model. Disruptions of the intestinal environment and barrier function in the infected mice were attenuated by BbY. Protection against the MDRAb infection was markedly potentiated by a synbiotic combination of BbY and GOS, although GOS by itself did not provide protection. Negative correlations were observed between intestinal MDRAb and BbY counts or acetic acid levels; positive correlations were observed between acetic acid levels and intestinal epithelium expression of tight-junction-related genes. These results demonstrated that the probiotic and synbiotic markedly potentiated protection against fatal intestinal infection caused by a multidrug-resistant bacterium. Probiotics and synbiotics are presumed to provide protection by compensation for the disrupted indigenous populations, thereby maintaining the intestinal environments and barrier functions otherwise targeted during opportunistic infection by MDRAb.
authors.affiliation: Yakult Central Institute, Yakult Honsha Co., Ltd., Kunitachi, Tokyo, Japan takashi-asahara@yakult.co.jp.
authors.forename: Takashi
authors.initials: T
authors.lastname: Asahara
authors.affiliation: Yakult Central Institute, Yakult Honsha Co., Ltd., Kunitachi, Tokyo, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Takahashi
authors.affiliation: Yakult Central Institute, Yakult Honsha Co., Ltd., Kunitachi, Tokyo, Japan.
authors.forename: Norikatsu
authors.initials: N
authors.lastname: Yuki
authors.affiliation: Yakult Central Institute, Yakult Honsha Co., Ltd., Kunitachi, Tokyo, Japan.
authors.forename: Rumi
authors.initials: R
authors.lastname: Kaji
authors.affiliation: Yakult Central Institute, Yakult Honsha Co., Ltd., Kunitachi, Tokyo, Japan.
authors.forename: Takuya
authors.initials: T
authors.lastname: Takahashi
authors.affiliation: Yakult Central Institute, Yakult Honsha Co., Ltd., Kunitachi, Tokyo, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Nomoto
mesh_terms: D000151:Acinetobacter Infections / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000472:pathogenicity*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001644:Bifidobacterium / Q000502:physiology*; D004195:Disease Models, Animal; D024901:Drug Resistance, Multiple, Bacterial; D005243:Feces / Q000382:microbiology; D005472:Fluorouracil / Q000494:pharmacology; D000069196:Gastrointestinal Microbiome / Q000187:drug effects; D007410:Intestinal Diseases / Q000821:virology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D019936:Probiotics / Q000494:pharmacology*; D058616:Synbiotics
chemical_list: D000900:Anti-Bacterial Agents; D005472:Fluorouracil